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Introduction:  Metabolic  syndrome  (MS)  is  an  independent  predictor  of  acute  cardiovascu-
lar events.  However,  few  studies  have  addressed  the  relationship  between  MS  and  stable
angiographic  coronary  artery  disease  (CAD),  which  has  a  different  pathophysiological  mech-
anism. We  aimed  to  study  the  independent  predictors  for  signiﬁcant  CAD,  and  to  analyze  the
impact of  MS  (by  the  AHA/NHLBI  deﬁnition)  on  CAD.
Methods: We prospectively  included  300  patients,  mean  age  64  ±  9  years,  59%  male,  admitted
for elective  coronary  angiography  (suspected  ischemic  heart  disease),  excluding  patients  with
known cardiac  disease.  All  patients  underwent  assessment  of  demographic,  anthropometric,
and laboratory  data  and  risk  factors,  and  subsequently  underwent  coronary  angiography.
Results: In the  study  population,  23.0%  were  diabetic,  40.5%  had  MS  (and  no  diabetes)  and
36.7% had  neither  diagnosis.  Signiﬁcant  CAD  was  present  in  51.3%  of  patients.  CAD  patients
were older  and  more  frequently  male  and  diabetic,  with  increased  triglycerides  and  glucose
and lower  HDL  cholesterol.  Abdominal  obesity  was  also  less  prevalent.  MS  was  not  associated
with the  presence  of  CAD  (OR  0.94,  95%  CI  0.59--1.48,  p=0.778).  Of  the  MS  components,  the
most important  predictors  of  CAD  were  increased  glucose  and  triglycerides.  Abdominal  obesity
was associated  with  a  lower  risk  of  CAD.  In  a  multivariate  logistic  regression  model  for  CAD,
independent  predictors  of  CAD  were  age,  male  gender,  glucose  and  triglycerides.  Body  mass
index had  a  protective  effect.
Conclusions:  Although  MS  is  associated  with  cardiovascular  events,  the  same  was  not  found
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Poderá  a  presenc¸a  de  síndrome  metabólica  predizer  a  presenc¸a  de  doenc¸a arterial
coronária  angiográﬁcamente  signiﬁcativa?
Resumo
Introduc¸ão:  A  síndrome  metabólica  (SM)  é  um  predizente  independente  de  eventos  cardio-
vasculares  agudos.  Contudo,  pouco  estudos  analisaram  a  relac¸ão  entre  SM  e  doenc¸a  arterial
coronária angiográﬁca  estável  (DAC),  que  apresenta  uma  diferente  mecanismo  ﬁsiopatológico.
Procurámos  identiﬁcar  os  factores  predizentes  independentes  para  DAC  e  analisar  o  impacto  da
presenc¸a de  SM  (pela  deﬁnic¸ão  da  AHA/NHLBI)  na  DAC.
Métodos: Analisamos  prospectivamente  300  indivíduos,  com  idade  media  de  64  ±  9  anos,  59%
do género  masculino,  admitidos  para  angiograﬁa  coronária  eletiva  por  suspeita  de  cardiopa-
tia isquémica,  tendo  sido  excluídos  os  doentes  com  antecedentes  de  doenc¸a  cardíaca.  Todos
os doentes  foram  submetidos  a  avaliac¸ão  demográﬁca,  antropométrica,  fatores  de  risco  e
laboratorial  e  subsequentemente  a  coronariograﬁa.
Resultados: Na  populac¸ão  do  estudo,  23,0%  eram  diabéticos,  40,5%  tinha  SM  (sem  diabetes)  e
36,7% nenhum  dos  anteriores  diagnósticos.  Veriﬁcou-se  DAC  signiﬁcativa  em  51,3%  dos  doentes.
Estes doentes  tinham  mais  idade,  mais  do  género  masculino,  diabéticos,  com  triglicéridos  e
glicemia aumentados  e  colesterol-HDL  baixo.  A  obesidade  abdominal  era  também  menos  preva-
lente. A  SM  não  se  associou  com  a  presenc¸a  de  DAC  (OR  0,94,  IC  95%  0,59--1,48,  p  =  0,778).  Os
factores  predizentes  mais  importantes  de  DAC  de  entre  os  componentes  de  SM  foram  a  glicemia
e os  triglicéridos  aumentados.  A  obesidade  abdominal  mostrou  menor  risco  de  DAC.  Num  mod-
elo de  regressão  logística  multivariável  para  DAC,  os  factores  predizentes  independentes  foram
a idade,  género  masculino,  glicemia,  triglicéridos.  O  Indíce  de  Massa  Corporal  mostrou  efeito
«protector».
Conclusões: Apesar da  SM  se  associar  a  eventos  cardiovasculares,  o  mesmo  não  se  veriﬁca  rela-
tivamente a  DAC  angiográﬁca  estável.  A  idade,  género,  diabetes  e  triglicéridos  são  os  factores
mais inﬂuentes  para  a  presenc¸a  de  DAC,  sendo  a  obesidade  abdominal  «protectora».
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besity  and  metabolic  syndrome  are  major  epidemics  of
he  21st  century  worldwide.1,2 The  best  available  evidence,
rom  three  consecutive  large  meta-analyses,  consistently
hows  that  individuals  with  metabolic  syndrome  are  at
ncreased  risk  of  cardiovascular  events  (two-fold  increase
n  cardiovascular  outcomes  --  cardiovascular  mortality,
yocardial  infarction  and  stroke  --  and  a  1.5-fold  increase
n  all-cause  mortality).3--5 They  also  demonstrated  that  car-
iovascular  risk  was  still  high  in  patients  with  the  metabolic
yndrome  but  without  diabetes.
Although  the  association  of  metabolic  syndrome  with
ardiovascular  events  is  clear,  the  association  with  stable
ngiographic  coronary  artery  disease  (CAD)  is  less  so,  the
ew  available  studies  being  based  on  small  samples  and
howing  contradictory  results.6--11 In  the  literature,  some
uthors  have  assessed  the  association  between  metabolic
yndrome,  diabetes  and  severity  of  angiographic  CAD  in
ross-sectional  and  longitudinal  studies,  but  they  either
onsidered  one  gender  or  studied  ethnicities  other  than  Cau-
asian,  or  they  did  not  compare  diabetic  and  non-diabetic
ndividuals.  In  a  larger  study  of  stable  CAD  patients,  the
resence  of  metabolic  syndrome  identiﬁed  increased  risk  of
eath  or  myocardial  infarction  but  did  not  have  independent
rognostic  signiﬁcance  after  adjustment  for  its  constituent
omponents.  Hypertension,  low  HDL  cholesterol  and  ele-




tThe  aim  of  the  present  study  was  to  assess  the  association
etween  metabolic  syndrome  and  angiographic  CAD.  We  also
ompared  individuals  with  metabolic  syndrome  and  those
ith  diabetes  (in  whom  the  association  with  CAD  is  clearly
stablished  and  for  some  authors  is  responsible  for  the
etabolic  syndrome’s  impact  on  cardiovascular  outcomes)
nd  with  a  control  group  with  neither  diagnosis  (‘‘Normal’’
roup).
ethods
his  was  an  observational  cross-sectional  study,  with
rospective  inclusion  of  patients  admitted  for  elective  coro-
ary  angiography  with  suspected  CAD  (stable  angina  and/or
schemia  documented  by  non-invasive  tests).  All  patients
ere  aged  ≥18  years.  Patients  with  previous  acute  coronary
yndrome,  myocardial  revascularization  procedure,  valvular
eart  disease,  congenital  heart  disease  or  cardiomyopathy
ere  excluded  from  the  study.  All  patients  gave  their  writ-
en  informed  consent  and  the  study  protocol  conforms  to
he  ethical  guidelines  of  the  1975  Declaration  of  Helsinki  as
eﬂected  in  prior  approval  by  the  local  institutional  ethics
ommittee.
Anthropometric  data  were  obtained  after  a 12-hour  fast,
ith  the  subject  in  light  clothing  and  barefoot.  Body  weight
as  measured  to  the  nearest  kilogram  using  a  digital  scale,
nd  height  to  the  nearest  centimeter  in  the  standing  posi-
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kilograms  divided  by  height  in  meters  squared.  Waist  cir-
cumference  (WC)  was  measured  to  the  nearest  centimeter,
with  the  subject  standing,  using  a  ﬂexible  non-stretch  tape
measure,  midway  between  the  lower  edge  of  the  rib  cage
and  the  iliac  crest.  Obesity  was  deﬁned  as  BMI  ≥30  kg/m2,
overweight  as  BMI  25--29.9  kg/m2,  and  normal  as  BMI
<25  kg/m2.
Blood  pressure  was  measured  on  several  occasions  dur-
ing  hospital  stay,  hypertension  being  deﬁned  by  a  previous
diagnosis  of  hypertension  or  the  presence  of  systolic  blood
pressure  ≥140  mmHg  or  diastolic  blood  pressure  ≥90  mmHg
(mean  of  two  consecutive  measurements).  Patients  who
self-reported  as  having  smoked  during  the  previous  six
months  were  classiﬁed  as  smokers.
A  venous  blood  sample  was  drawn  after  a  12-hour
overnight  fast.  All  the  samples  were  analyzed  at  the  hos-
pital’s  central  laboratory.  Serum  glucose,  total  cholesterol
and  triglycerides  were  determined  using  standard  automatic
enzymatic  methods.  HDL  cholesterol  was  determined  after
speciﬁc  precipitation  and  LDL  cholesterol  was  determined
by  the  Friedewald  formula.  Blood  insulin  was  determined  by
electrochemiluminescence.
The  metabolic  syndrome  was  deﬁned  by  the  most  recent
deﬁnition  from  the  American  Heart  Association/National
Heart,  Lung  and  Blood  Institute  (AHA/NHLBI),  consisting  of
≥3  of  the  following  criteria:  fasting  glucose  ≥100  mg/dl
or  antidiabetic  treatment;  blood  pressure  ≥130/85  mmHg
or  antihypertensive  medication;  triglycerides  ≥150  mg/dl  or
speciﬁc  treatment  for  this  lipid  abnormality;  HDL  choles-
terol  <50  mg/dl  in  women  and  <40  mg/dl  in  men  or  speciﬁc
treatment  for  this  lipid  abnormality;  WC  ≥88  cm  in  women
and  ≥102  cm  in  men.13 Diabetes  was  recorded  by  the
investigator  based  on  patient  history,  increased  glucose
(fasting  level  ≥126  mg/dl),  or  concomitant  use  of  speciﬁc
therapies.
Coronary  angiography  was  performed  by  the  standard
Judkins  technique.  The  coronary  angiograms  were  analyzed
using  quantitative  coronary  angiography  software,  Cardio-
vascular  Measurement  System  (QCA-CMS)  version  6.0  (Medis
Medical  Imaging  Systems,  Leiden,  The  Netherlands)  by  a
single  operator  blinded  to  the  diagnosis.  An  automated
edge  detection  algorithm  determined  vessel  centerline  and
contour,  and  absolute  reference  vessel  and  minimum  lumen
diameters  were  determined  using  the  calibration  factor.
Percentage  stenosis  was  calculated  from  minimum  lumen
diameter  and  a  normal  reference  value  obtained  as  an
extrapolation  of  the  proximal  and  distal  segments  surround-
ing  the  stenosis.  Obstructive  CAD  was  deﬁned  as  stenosis
of  50%  or  more  in  any  coronary  vessel.  The  severity  of  CAD
was  assessed  by  the  Gensini  score,  a  previously  validated
method,  which  grades  narrowing  of  the  coronary  artery
lumen  as:  1  for  1--25%  narrowing,  2  for  26--50%  narrowing,
4  for  51--75%  narrowing,  8  for  76--90%  narrowing,  16  for
91--99%  narrowing  and  32  for  total  occlusion.14 This  score
was  then  multiplied  by  a  factor  from  0.5  to  5  that  takes
into  account  the  importance  of  the  lesion’s  position  in  the
coronary  arterial  tree.
The  interclass  correlation  coefﬁcients  for  intrareader
reproducibility  were  0.950  for  Gensini  score  and  0.724
to  0.947  for  vessel  dimension  (analyzed  for  differ-
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tatistical  analysis
he  statistical  analysis  was  conducted  using  PASW  Statis-
ics  18.0  (SPSS  Inc,  IL,  Chicago,  USA).  A  p-value  <0.05  was
onsidered  statistically  signiﬁcant.
Quantitative  variables  were  expressed  as
ean  ±  standard  deviation  if  normally  distributed  and
s  median  and  inter-quartile  range  otherwise.  Qualitative
ariables  are  described  as  percentages.  The  Student’s  t
est  or  the  Mann--Whitney  U-test  were  used  for  between-
roup  comparisons  of  continuous  variables  (according  to
istribution  characteristics).  For  comparisons  of  more  than
wo  groups,  the  one-way  ANOVA  test  or  the  Kruskal--Wallis
est  was  used,  as  appropriate.  The  chi-square  test  was
sed  for  between-group  comparisons  of  categorical  varia-
les.  For  some  continuous  highly  skewed  variables  a  base
0  logarithmic  transformation  was  performed  that  was  used
n  the  subsequent  analysis.  Blood  glucose  required  a  natural
ogarithmic  transformation  to  improve  normality.  Bivariate
ogistic  regression  analysis  was  used  to  identify  indepen-
ent  risk  factors  for  CAD.  Backward  multivariate  logistic
egression  analysis  (with  CAD  as  the  outcome  variable)  was
erformed  to  determine  independent  predictors  of  CAD.
ll  variables  with  a  p-value  <0.10  in  bivariate  analysis  were
ncluded  in  the  analysis.
esults
 total  of  300  patients  were  included  in  the  study,  with
 mean  age  of  64  ±  9  years  (aged  38--86  years),  59%  male
Table  1).  Signiﬁcant  coronary  artery  disease  was  present
n  51.3%  of  patients,  but  was  signiﬁcantly  less  prevalent  in
omen  (35.8%  vs.  62.1%,  p  <  0.001).  The  Gensini  score  was
lso  signiﬁcantly  higher  in  men:  9.5  (5.00--17.75)  vs.  6.00
3.00--10.00),  p  <  0.001.  Patients  with  signiﬁcant  CAD  were
lder,  more  frequently  male  and  diabetic,  and  had  higher
lood  glucose  and  triglycerides  and  lower  HDL  cholesterol
Table  1).
The  prevalence  of  the  metabolic  syndrome  by  the
HA/NHLBI  deﬁnition  in  the  present  population  was  55.3%.
he  presence  of  CAD  was  associated  with  diabetes,  male
ender,  older  age  and  increased  triglycerides  and  glucose
Tables  2  and  3).  On  the  other  hand,  patients  with  abdomi-
al  obesity  and  increased  HDL  cholesterol  were  less  likely  to
ave  CAD.  Lipid-lowering  therapy  was  not  associated  with
ower  CAD  prevalence.  Patients  with  metabolic  syndrome
id  not  have  an  increased  risk  of  signiﬁcant  CAD.  Analyzing
he  relationship  between  metabolic  syndrome  components
nd  CAD  prevalence,  as  well  as  with  Gensini  score,  we  found
 non-linear  association,  because  patients  with  no  compo-
ent  present  had  the  lowest  prevalence  as  well  as  the  lowest
ensini  score,  and  patients  with  ﬁve  components  had  the
ighest  values,  but  no  signiﬁcant  difference  was  found  in
he  intermediate  groups  (Figures  1  and  2).
Overall,  the  prevalence  of  diabetes  was  23.0%,  metabolic
yndrome  (in  non-diabetic  patients)  40.5%,  and  36.7%  had
either  diagnosis  (Table  4).  CAD  prevalence  was  65.2%  in
he  diabetic  group,  46.3%  in  the  metabolic  syndrome  group
nd  48.2%  in  the  group  with  neither  diagnosis  (p=0.003),
ith  the  only  signiﬁcant  differences  between  diabetic
atients  and  the  other  two  groups.  Even  after  inclusion  of
772  A.T.  Timóteo  et  al.
Table  1  Characteristics  of  the  study  population  by  presence  of  coronary  artery  disease.
Characteristics  Total
Mean  ±  SD
Median  (IQR)  %
CAD
Mean  ±  SD
Median  (IQR)  %
No  CAD
Mean  ±  SD
Median  (IQR)  %
p
Age  (years)  64.4  ±  9.2  66.2  ±  9.2  63.4  ±  9.9  0.003
Male gender  (%)  59  71  46  0.001
Risk factors  (%)
Hypertension  79  87  84  0.604
Hyperlipidemia  70  70  69  0.957
Smoking 9  11  8  0.398
Diabetes 23 29 16  0.013
Laboratory data
Glucose  (mg/dl) 100  (92--115)  104  (93--124)  97  (91--106)  0.001
Insulin (U/ml)  8.6  (5.7--13.6)  8.8  (5.8--14.1)  8.5  (5.5--12.5)  0.471
HOMA index  2.3  (1.4--3.8)  2.3  (1.5--4.1)  2.1  (1.3--3.2)  0.129
Total cholesterol  (mg/dl)181  (155--213)  182  (158--218)  177  (152--207)  0.208
HDL cholesterol  (mg/dl)  43  (36--54)  41  (34--50)  47  (40--55)  <0.001
LDL cholesterol  (mg/dl)  114  (93--136)  114  (97--141)  114  (89--133)  0.141
Triglycerides (mg/dl)  97  (68--134)  100  (71--146)  93  (63--124)  0.019
CAD: coronary artery disease; HOMA: homeostasis model assessment; IQR: interquartile range; SD: standard deviation.
Table  2  Prevalence  of  coronary  artery  disease  by  risk  factor.
Risk  factor Present  Absent  OR  (95%  CI)  p
Hypertension  52.1  46.5  1.25  (0.66--2.39)  0.604
Diabetes 65.2  47.2  2.10  (1.20--3.67)  0.013
Smoking 60.7  50.4  1.52  (0.69--3.37)  0.398
Abdominal obesity  44.3  61.1  0.51  (0.32--0.81)  0.006
Low HDL  cholesterol  54.5  48.4  1.28  (0.81--2.01)  0.347
High triglycerides  62.1  48.3  1.76  (1.00--3.07)  0.065
High blood  glucose  59.0  42.4  1.95  (1.23--3.09)  0.006
Male gender  62.1  35.8  2.95  (1.83--4.75)  <0.001
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iabetic  patients  with  metabolic  syndrome  in  the  metabolic
yndrome  group,  there  was  no  signiﬁcant  increase  of  CAD
revalence  in  this  group  compared  to  diabetics  alone  (50.6%
s.  70.8%,  p=0.127).
After  adjustment  for  age  and  gender,  only  diabetes  was
ssociated  with  CAD,  not  metabolic  syndrome  (Table  5).  The

















igure  1  Prevalence  of  signiﬁcant  coronary  artery  disease
CAD)  according  to  the  number  of  metabolic  syndrome  com-















lith  CAD  were  increased  glucose  and  triglycerides,  while
bdominal  obesity  showed  a  protective  effect  (Table  6).
ndependent  predictors  of  CAD  were  age,  male  gender,  dia-
etes  (and  increased  glucose)  and  increased  triglycerides.
MI  was  a  protective  factor  (Table  7).
In  our  population,  88%  of  the  patients  had  a  non-invasive
est  positive  for  myocardial  ischemia.  The  others  underwent
oronary  angiography  without  a  previous  non-invasive  test
or  ischemia.  In  the  group  with  a  positive  treadmill  stress
est,  only  49.3%  had  signiﬁcant  angiographic  coronary  artery
isease.  In  the  group  with  positive  cardiac  scintigraphy,
4.3%  had  signiﬁcant  coronary  artery  disease.  In  patients
ith  a  positive  functional  test  for  ischemia,  49.0%  of  the
roup  without  metabolic  disorder,  45.7%  of  patients  with
etabolic  syndrome  and  65.6%  of  diabetic  patients  had  sig-
iﬁcant  angiographic  coronary  artery  disease  (p=0.039).iscussion
e  found  in  our  study  that  metabolic  syndrome  preva-
ence  is  not  associated  with  the  prevalence  of  signiﬁcant
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Table  3  Bivariate  analysis  for  signiﬁcant  coronary  artery  disease.
B  Wald  OR  (95%  CI)  p
Age 0.039 8.697  1.04  (1.01--1.07)  0.003
Male gender  1.081  19.670  2.95  (1.83--4.75)  <0.001
Smoking 0.421  1.076  1.52  (0.69--3.37)  0.300
Hyperlipidemia  0.045  0.032  1.05  (0.64--1.71)  0.858
Diabetes 0.741  6.760  2.10  (1.20--3.67)  0.009
Waist circumference  −0.005  0.271  1.00  (0.98--1.01)  0.603
BMI −0.052  3.487  0.95  (0.90--1.00)  0.062
BMI groups
Normal Ref. --  --  --
Overweight −0.110 0.129  0.90  (0.49--1.63) 0.720
Obese −0.638 3.590  0.53  (0.27--1.02) 0.058
Lipid-lowering  therapy  0.200  0.720  1.22  (0.77--1.94)  0.396
Metabolic syndrome  components
Hypertension  0.225  0.466  1.25  (0.66--2.39)  0.495
Abdominal obesity  −0.683  8.226  0.51  (0.32--0.81)  0.004
High-blood glucose  0.669  8.112  1.95  (1.23--3.09)  0.004
Low HDL  cholesterol  0.244  1.110  1.28  (0.81--2.01)  0.291
Hypertriglyceridemia  0.563  3.890  1.76  (1.00--3.07)  0.049
Metabolic syndrome  (AHA/NHLBI)  −0.066  0.079  0.94  (0.59--1.48)  0.778
No. of  metabolic  syndrome  components  0.127  1.739  1.14  (0.94--1.37)  0.187
Metabolic groups
Normal  Ref.  --  --  --
Metabolic syndrome  −0.076  0.084  0.93  (0.55--1.55)  0.773
Diabetes 0.701  4.900  2.02  (1.08--3.75)  0.027
Laboratory results
LnGlucose 1.582 9.465  4.86  (1.78--1332)  0.002
LogTotal cholesterol 1.407  1.473  4.08  (0.42--39.60)  0.225
LogLDL cholesterol 1.386 2.463  4.00  (0.71--22.56)  0.117
LogHDL cholesterol −3.451  11.635  0.03  (0.004--0.23)  0.001
LogTriglycerides 1.455 8.121  4.29  (1.58--11.66)  0.004
LogInsulin 0.451 1.603  1.57  (0.78--3.16)  0.206
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angiographic  CAD.  On  the  other  hand,  diabetes  was  highly
correlated  with  CAD.  The  most  important  components  of
metabolic  syndrome  to  predict  CAD  are  increased  glucose
and  triglycerides,  with  abdominal  obesity  being  protective.
The  independent  predictors  for  signiﬁcant  CAD  in  this  high-
risk  population  are  age,  male  gender,  high  glucose,  and
high  triglycerides.  Increased  BMI  was  protective  against  CAD.
Unexpectedly,  total  cholesterol  and  LDL  cholesterol  showed
no  association.
Since  the  ﬁrst  description  of  the  metabolic  syndrome
by  Raven  in  1988,  several  deﬁnitions  have  been  pub-
lished,  including  those  of  the  World  Health  Organization,
the  National  Cholesterol  Education  Program  (NCEP)  and  the
International  Diabetes  Federation.15--18 Of  these,  the  NCEP
deﬁnition  has  emerged  as  the  most  widely  used,  primar-
ily  because  it  provides  a  relatively  simple  approach  for
diagnosing  metabolic  syndrome  by  employing  easily  mea-
surable  risk  factors.  This  deﬁnition  has  been  updated  by




bel assessment; Ln: natural logarithmic transformation; Log: base
n accordance  with  the  American  Diabetes  Association;  the
ew  deﬁnition  includes  patients  being  treated  for  dyslipid-
mia,  hyperglycemia,  or  systemic  hypertension.13,19
Two  meta-analyses  investigating  metabolic  syndrome
rior  to  2005,  not  including  the  new  deﬁnition,3,4 showed
hat  metabolic  syndrome  was  associated  with  higher  cardio-
ascular  risk,  particularly  in  women.  A  recent  meta-analysis
ncluding  studies  with  the  AHA/NHLBI  deﬁnition  showed
hat  overall,  the  metabolic  syndrome  was  associated  with
 two-fold  increase  in  risk  of  cardiovascular  disease,  car-
iovascular  mortality,  and  stroke,  and  a  1.5-fold  increase  in
isk  of  all-cause  mortality.5 Thus,  patients  with  metabolic
yndrome  are  at  higher  risk  for  cardiovascular  outcomes
han  for  all-cause  mortality.  Even  in  the  absence  of  type
 diabetes,  the  metabolic  syndrome  was  still  associated
ith  an  increased  risk  of  cardiovascular  endpoints,  which
oes  against  the  argument  that  the  impact  of  metabolic
yndrome  derives  from  its  frequent  association  with  dia-
etes.  Cardiovascular  risk  with  the  AHA/NHLBI  deﬁnition
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Age  (years)  62.6  ±  9.9  65.2  ±  9.2  66.0  ±  7.3  0.024
Male gender  (%)  65.5  53.7  58.0  0.190
Smoking (%)  11.8  7.4  8.7  0.509
Hyperlipidemia  (%)  63.6  73.6  72.5  0.222
WC (cm)  95  (88--100)  103  (96--110)  98  (90--106)  <0.001
BMI (kg/m2)  25.9  (24.0--28.3)  29.4  (27.3--32.0)  27.3  (25.0--31.2)  <0.001
BMI groups  (%) <0.001
Normal 32.7  6.6  24.6
Overweight 51.8  52.9  42.0
Obese 15.5  40.5  33.3
Treatment  (%)
Anti-hypertension  64.5  82.6  94.2  <0.001
Lipid-lowering  53.6  59.5  71.0  0.069
Anti-diabetic  0  0  87.0  <0.001
MS component  (%)
Hypertension 75.5  93.4  88.4  <0.001
Increased glucose 17.3  60.3  100.0  <0.001
Obesity 29.1  82.6  60.9  <0.001
High triglycerides 7.3  34.7  23.2  <0.001
Low HDL  cholesterol 20.0  73.6  49.3  <0.001
Laboratory data
Blood  glucose  (mg/dl)  91  (86--97)  101  (95--109)  147  (126--178)  <0.001
Total cholesterol  (mg/dl)  185  (160--214)  182  (159--219)  168  (142--206)  0.025
HDL cholesterol  (mg/dl)  51  (41--60)  40  (34--47)  43  (33--51)  <0.001
LDL cholesterol  (mg/dl)  116  (98--140)  119  (95--142)  99  (82--125)  0.011
Triglycerides  (mg/dl)  78  (55--100)  111  (83--167)  106  (73--142)  <0.001
Insulin (U/ml)  6.7  (4.2--9.0)  11.6  (7.7--17.7)  9.2  (6.5--16.0)  <0.001
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as  also  similar  to  that  with  the  NCEP  deﬁnition.  Although
he  pathophysiological  mechanism  by  which  the  metabolic
yndrome  increases  cardiovascular  risk  remains  the  sub-
ect  of  debate,  insulin  resistance  is  often  put  forward  as
he  underlying  component.20,21 Insulin  resistance  is  asso-
iated  with  lipid  imbalances  and  with  prothrombotic  and
roinﬂammatory  states.20,22 More  recent  deﬁnitions  empha-
ize  central  obesity  as  the  underlying  component,  which  is
ssociated  with  adiponectin/leptin  imbalances  and  conse-




Table  5  Predictive  ability  for  coronary  artery  disease  in  each  me
B  
Age  0.040  
Male gender  1.152  
Metabolic groups
Normal  Ref.  
Metabolic syndrome  −0.042  
Diabetes 0.733  
CI: conﬁdence interval; OR: odds ratio; Ref.: reference group.abolic syndrome; WC: waist circumference.
The  prognostic  importance  of  the  metabolic  syndrome
ompared  to  that  of  the  sum  of  its  individual  components
as  repeatedly  been  challenged.  In  a  cohort  study,  the  risk
f  cardiovascular  mortality  associated  with  metabolic  syn-
rome  was  similar  to  the  risk  associated  with  impaired
asting  glucose  and  systemic  hypertension.23 Furthermore,
n  a  systematic  review  of  seven  clinical  trials,  the  metabolic
yndrome  by  the  NCEP  deﬁnition  was  no  longer  an  indepen-
ent  predictor  of  atherosclerotic  plaque  progression  after
djustment  for  its  individual  components.24 However,  most
tabolic  group,  adjusted  for  age  and  gender.
Wald  OR  (95%  CI)  p
8.175  1.04  (1.01--1.07)  0.004
20.530  3.16  (1.92--5.21)  <0.001
--  --  --
0.022  0.96  (0.55--1.66)  0.881
4.702  2.08  (1.07--4.04)  0.030
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Table  6  Predictive  ability  for  coronary  artery  disease  of  each  metabolic  syndrome  component,  adjusted  for  age  and  gender.
B Wald  OR  (95%  CI)  p
Age 0.044  8.865  1.05  (1.02--1.08)  0.003
Male gender  0.842  8.361  2.32  (1.31--4.11)  0.004
Hypertension  0.125  0.122  1.13  (0.56--2.28)  0.727
Abdominal obesity  −0.699  5.144  0.50  (0.27--0.91)  0.023
Glucose ≥100  mg/dl  0.567  4.908  1.76  (1.07--2.91)  0.027
Low HDL  cholesterol  0.410  2.336  1.51  (0.89--2.55)  0.126
Triglycerides  ≥150  mg/dl  0.698  4.873  2.01  (1.08--3.74)  0.027
CI: conﬁdence interval; OR: odds ratio.
Table  7  Independent  predictors  for  signiﬁcant  coronary  artery  disease.
B Wald OR  (95%  CI) p
Age  0.037  67.05  1.04  (1.01--1.07)  0.010
Male gender  0.893  11.039  2.44  (1.44--4.14)  0.001
Body mass  index −0.078  5.773  0.93  (0.87--0.99)  0.016
LogTriglycerides 1.321  5.397  3.75  (1.23--11.42)  0.020
LnGlucose 1.277  5.230  3.59  (1.20--10.72)  0.022
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Variables in the analysis: age, gender, diabetes, body mass index,
published  reports  appear  to  indicate  that  the  syndrome  pre-
dicts  cardiovascular  events  and/or  diabetes  independently
of  other  cardiovascular  risk  factors.
In  the  MESYAS  study,  conducted  among  Spanish  work-
ers  and  thus  similar  to  Portuguese  populations,  except  for
the  signiﬁcant  male  predominance  in  the  Spanish  study,  it
was  demonstrated  that  metabolic  syndrome  is  associated
with  a  substantial  increase  in  the  risk  of  developing  CAD.25
However,  the  metabolic  syndrome  components  confer  very
different  intensities  of  independent  risk,  from  the  high
independent  risk  of  hypertriglyceridemia  (long  known  but
overlooked)  to  the  almost  complete  absence  of  an  indepen-
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Figure  2  Gensini  score  according  to  the  number  of  metabolic
























ducose, LogHDL cholesterol, LogTriglycerides.
hich  seems  contradictory).  In  the  absence  of  obesity,
hree  other  higher  risk  criteria  are  required  for  the  diag-
osis.  As  a  result,  there  is  heterogeneity  of  risk  among
atients  with  metabolic  syndrome,  depending  on  the  par-
icular  criteria  used  for  a  diagnosis.  The  cardiovascular
isease  burden  derived  from  obesity  is  probably  mediated
y  the  presence  of  the  other  known  metabolic  risk  factors,
hich  cluster  more  often  in  the  presence  of  obesity.  Sim-
lar  results  were  obtained  in  our  study  and  this  might  also
xplain  some  discrepancies  in  the  results  between  studies
ccording  to  the  predominant  type  of  clusters  in  a  speciﬁc
opulation.
However,  our  results  are  different  from  the  previously
entioned  large  meta-analysis  with  regard  to  the  associ-
tion  between  metabolic  syndrome  and  coronary  disease.
urs  is  an  angiographic  study  that  provides  different  infor-
ation  from  that  obtained  in  epidemiological  studies  that
nalyze  cardiovascular  events.  Acute  cardiovascular  events
ave  different  pathophysiological  mechanisms  from  those  in
table  coronary  atherosclerotic  plaque.  Vulnerable  plaques
re  generally  characterized  as  having  a  thin  inﬂamed  ﬁbrous
ap  over  a  large  lipid  core  with  activated  macrophages  near
he  cap.26 In  previous  studies,  the  strongest  independent
redictor  of  coronary  plaque  rupture  was  the  presence  of
etabolic  syndrome,  as  well  as  positive  remodeling  at  the
ulprit  lesion  and  an  elastic  membrane  cross-sectional  area
14  mm2.26 Among  the  components  of  metabolic  syndrome,
bdominal  obesity  and  low  serum  HDL  cholesterol  were  sig-
iﬁcant  independent  predictors  for  culprit  coronary  plaque
upture.  Thus,  vulnerable  coronary  plaque  rupture  is  asso-
iated  with  metabolic  syndrome,  especially  with  abdominal
besity  and  low  HDL  cholesterol.  These  results  might  explain
he  association  of  metabolic  syndrome  with  cardiovascu-
ar  events;  stable  coronary  atherosclerotic  plaques  have  a
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A  Turkish  angiographic  study  in  184  patients  showed  that
iabetic  patients  had  signiﬁcantly  higher  Gensini  scores.6
owever,  metabolic  syndrome  patients  (by  the  NCEP  def-
nition)  did  not  have  signiﬁcantly  different  Gensini  scores.
lso  when  evaluating  diabetic  and  non-diabetic  patients  sep-
rately,  non-diabetic  patients  with  metabolic  syndrome  had
lightly  higher  scores,  but  without  statistical  signiﬁcance.
either  any  single  metabolic  syndrome  component  nor  gen-
er  revealed  a  signiﬁcant  relationship  with  coronary  disease
everity.
A  study  by  Bayturan  et  al.  in  the  USA  with  intravas-
ular  ultrasound  imaging  revealed  that  a  diagnosis  of
iabetes  was  associated  with  a  greater  burden  and  pro-
ression  of  coronary  atherosclerosis,  despite  the  presence
f  fewer  individual  cardiovascular  risk  factors,  than  a  diag-
osis  of  metabolic  syndrome,  underscoring  the  importance
f  diabetes  and  its  impact  on  the  atherosclerotic  process
ccurring  within  the  arterial  wall.27 This  reinforces  the
therogenicity  concept  of  diabetes,  which  may  exert  dele-
erious  proatherogenic  effects  by  glycation,  inﬂammation,
nd  oxidative  stress.  Furthermore,  diabetes  was  accom-
anied  by  vascular  constriction  and  small  lumen  volumes,
espite  the  presence  of  more  extensive  atheroma  burden.
n  the  same  study,  metabolic  syndrome  was  associated  with
arger  vessel  dimensions  and  no  greater  disease  burden
compared  to  patients  with  neither  condition),  suggesting
ifferent  effects  on  remodeling.  This  highlights  clear  dif-
erences  between  metabolic  syndrome  and  diabetes  with
egard  to  how  the  vessel  wall  responds  to  plaque  accu-
ulation.  Another  study  in  women  showed  that  women
ith  diabetes  had  more  severe  angiographic  disease  than
hose  without  diabetes,  while  no  association  was  found
etween  angiographic  scores  and  metabolic  syndrome.  In
ultivariate  analysis,  high  triglycerides  and  low  HDL  were
redictors  of  angiographically  proven  CAD.8 In  our  study,  we
lso  observed  a  direct  relationship  between  diabetes  and
AD  and  no  relationship  with  metabolic  syndrome.  We  also
onﬁrmed  the  importance  of  triglycerides  as  a  predictor  of
AD.
The  absence  of  association  between  total  cholesterol  and
DL  cholesterol  with  CAD  may  be  explained  by  the  high  rate
f  lipid-lowering  therapy  use  in  our  population,  which  was
0%  (56.6%  with  statins,  1.7%  with  ﬁbrates  and  1.7%  with
oth).  This  may  explain  the  relatively  low  levels  of  total
holesterol  and  LDL  cholesterol;  almost  75%  of  the  study
opulation  had  LDL  cholesterol  <130  mg/dl.  However,  lipid-
owering  therapy  by  itself  was  not  associated  with  CAD.
 recent  study  demonstrated  that  in  patients  with  low  lev-
ls  of  LDL  cholesterol  (<130  mg/dl),  the  lipid  abnormalities
ith  highest  impact  in  cardiovascular  events  are  indeed  HDL
holesterol  and  triglycerides,  as  our  results  show.28
Obesity  had  a  protective  effect  for  CAD.  Other  authors
ave  explained  this  inverse  relationship,  described  as  the
besity  paradox,  as  a  result  of  bias  caused  by  different
aseline  characteristics,  since  these  patients  are  usually
ounger.29,30 However,  in  our  population,  obese  patients  had
imilar  ages  (65  ±  9  years)  to  overweight  (64  ±  9  years)  and
ormal  BMI  patients  (65  ±  10  years,  p=NS).  Multivariate  anal-
sis  also  adjusted  the  results  for  age.  The  comorbidities
sually  associated  with  low  and  high  BMI  are  also  sug-
ested  as  an  explanation  for  the  better  outcome  observed
n  overweight  patients  after  acute  coronary  syndromes.
p
l
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owever,  in  our  study,  obese  patients  showed  a  trend  to
ower  CAD  prevalence,  but  not  overweight  patients.  This
ay  be  explained  by  the  fact  that,  as  previously  shown,  BMI
s  directly  related  to  coronary  vessel  diameter.31 This  leads
s  to  conclude  that  to  cause  50%  stenosis,  the  atheroscle-
otic  plaque  needs  to  be  signiﬁcantly  thicker  in  high  BMI
atients  than  in  low  BMI  patients.
The  relationship  between  metabolic  syndrome  and
unctional  tests  for  ischemia  is  also  interesting.  In  our
opulation,  a large  number  of  patients  had  a  previous
unctional  test  documenting  the  presence  of  myocardial
schemia.  It  would  be  expected  that  the  increased  use
f  non-invasive  testing  to  rule  out  ischemia  prior  to  the
rocedure  should  have  resulted  in  more  effective  risk  strat-
ﬁcation,  enabling  identiﬁcation  of  patients  who  would  be
ore  likely  to  beneﬁt  from  cardiac  catheterization  and
deally  reducing  the  use  of  invasive  procedures  in  those
ho  do  not  have  obstructive  disease.  However,  this  was
ot  the  case;  only  half  of  these  patients  had  signiﬁcant
ngiographic  CAD.  Patients  with  chest  pain  and  normal
r  non-obstructive  coronary  angiograms  are  predominately
omen,  and  many  have  a  prognosis  that  is  not  as  benign  as
reviously  thought.32 Recent  data  suggest  that  ST-segment
hanges  and  reversible  myocardial  perfusion  defects  in
atients  with  ‘‘normal’’  coronary  arteries  may  reﬂect  true
yocardial  ischemia  likely  related  to  atherosclerotic  dis-
ase  of  the  more  distal  coronary  circulation  and  not  a  false
ositive  result.32 Assessment  of  endothelial  function  could
elp  identify  patients  at  risk  for  future  cardiac  events.  In
atients  with  metabolic  syndrome,  the  association  between
he  results  of  functional  testing  and  of  coronary  angiography
ere  similar  to  ‘‘normal’’  patients.  Only  in  diabetic  patients
as  this  association  stronger.  This  suggests  a  stronger  asso-
iation  of  diabetes  with  epicardial  CAD,  conﬁrming  the
revious  conclusions  of  Bayturan  et  al.  using  intravascular
ltrasound.27
In  conclusion,  as  opposed  to  previous  epidemiological
tudies  on  prediction  of  cardiovascular  events,  metabolic
yndrome  is  not  a  predictor  of  angiographic  CAD.  Diabetes
and  blood  glucose)  remained  among  the  most  important
redictors,  as  well  as  age,  male  gender  and  triglycerides.
MI  appeared  to  be  protective  of  CAD.
imitations
his  was  a  cross-sectional  study,  and  as  such,  it  is  not  pos-
ible  to  establish  a  causal  relationship  since  no  information
rom  follow-up  was  analyzed  and  subjects  only  underwent  a
ingle  coronary  angiogram.
The  sample  is  relatively  small,  although  it  is  larger  than
n  other  studies  and  was  calculated  for  a  precision  of  5%  and
 power  of  80%.
Our  results  are  only  applicable  to  populations  similar
o  ours.  In  this  population,  60%  of  patients  were  under
ipid-lowering  therapy  and  almost  75%  had  LDL  cholesterol
130  mg/dl.  We  also  excluded  patients  with  known  heart
isease.This  was  an  angiographic  study  and  as  such,  coronary
laque  morphology  was  not  directly  assessed.  Intravascu-
ar  ultrasound  enables  cross-sectional  imaging  of  coronary
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atherosclerotic  plaque  in  vivo; it  is  considered  the  gold
standard  technique.  With  quantitative  coronary  angiography
analysis,  we  measured  reference  diameter  and  percent-
age  diameter  stenosis.  However,  it  has  been  reported  that
this  measurement  can  be  misleading,  because  patients  with
similar  measurements  on  angiography  might  have  different
vessel  and  plaque  volume  when  assessed  by  intravascular
ultrasound.  In  fact,  in  some  patients,  vessels  might  have
compensatory  enlargement  to  prevent  building  atheroma
from  encroaching  into  the  lumen,  thereby  concealing  the
presence  of  a  lesion  when  angiography  is  performed.10
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